deltatrials
Completed PHASE2 INTERVENTIONAL NCT00002826

Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer

A PILOT PHASE II TRIAL OF PSC 833 MODULATION OF MULTIDRUG RESISTANCE TO PACLITAXEL IN THE TREATMENT OF METASTATIC CARCINOMA OF THE BREAST

Sponsor: Eastern Cooperative Oncology Group

Conditions Breast Cancer
Interventions paclitaxel valspodar
Updated 7 times since 2017 Last updated: Jun 5, 2023 Started: Aug 14, 1997 Primary completion: Nov 30, 2003
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Breast Cancer and is currently completed. Eastern Cooperative Oncology Group leads this study, which shows 7 recorded versions since 1997 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2023 · 30 months · monthly snapshotCompleted~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jul 2023 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Aug 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eastern Cooperative Oncology Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations